Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | BCL9 | O00512 | 17/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 17/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23387200 | 1.00 | MTNR1A (0.52) | MTNR1AMTNR1BBCL9CTNNB1PPARA | |
| SCHEMBL29689580 | 0.90 | MTNR1A (0.52) | MTNR1AMTNR1BBCL9CTNNB1PPARA | |
| SCHEMBL22499998 | 0.87 | MTNR1A (0.69) | MTNR1AMTNR1B | |
| SCHEMBL22499995 | 0.87 | MTNR1A (0.69) | MTNR1AMTNR1B | |
| SCHEMBL21624746 | 0.81 | ME3 (0.51) | MTNR1AMTNR1B | |
| SCHEMBL21624749 | 0.81 | ME3 (0.51) | MTNR1AMTNR1B | |
| SCHEMBL22499993 | 0.75 | BCL9 (0.51) | BCL9CTNNB1PPARA | |
| SCHEMBL31258419 | 0.74 | CTNNB1 (0.54) | MTNR1AMTNR1BBCL9CTNNB1 | |
| SCHEMBL29139446 | 0.74 | CTNNB1 (0.54) | MTNR1AMTNR1BBCL9CTNNB1 | |
| SCHEMBL29139440 | 0.74 | CTNNB1 (0.54) | MTNR1AMTNR1BBCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | claimed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | claimed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | claimed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | MTNR1A 832/4885MTNR1B 557/4885BCL9 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.